Despite conflicting data, most research indicates that changes identified in the core promoter region in the MT2A gene near the TATA box may be considered as novel biomarkers of risk and tumor invasiveness, as well as a potential new therapeutic targets for treatment strategies to modify or inhibit neoplastic development and progression of various types of tumors [5, 10, 18, 20–23]. Here, MT2A is linked to neoplasm.